MALIGNANT BEHAVIOR AND CELLULAR ANTIGEN EXPRESSION

恶性行为和细胞抗原表达

• 批准号: 3163860
• 负责人: GEORGE KLEIN
• 金额: $ 11.25万
• 依托单位: KAROLINSKA INSTITUTE
• 依托单位国家: 美国
• 财政年份: 1980
• 资助国家: 美国
• 起止时间: 1980-01-01 至 1992-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3163860
• 关键词: Burkitt's lymphoma; Epstein Barr virus; L cell; Retroviridae disease; antibody dependent killer cell; cell differentiation; cell fusion; cell transformation; chromosome disorders; chromosome translocation; clone cells; cytogenetics; gene expression; genetic manipulation; genetic mapping; genetically modified animals; human tissue; hybrid cells; immune response genes; immunogenetics; immunoglobulin genes; laboratory mouse; laboratory rat; leukemia virus; linkage mapping; lymphoma; major histocompatibility complex; messenger RNA; molecular oncology; murine leukemia virus; natural gene amplification; neoplasm /cancer genetics; neoplasm /cancer immunology; oncogenes; oncogenic virus; plasmacytic leukemia; sarcoma; simian virus 40; surface antigens; tumor antigens; viral carcinogenesis; viral leukemogenesis; virus antigen; virus cytopathogenic effect; virus replication; xenotransplantation

This project is based on our earlier findings concerning the role of the IgH/myc juxtaposition in the genesis of murine plasmacytoma (MPG), rat immunocytoma (RIC) and human Burkitt lymphoma (BL) and the role of chr 15 trisomy in murine T-cell leukemia. This field has been largely initiated by our cytogenetic findings and derived working hypotheses, made under this grant. It is now pursued at numerous laboratories. We have chosen to concentrate our continued work on a few selected topics, where our laboratory has special experience, materials and/or has developed new working hypotheses. Our current aims are the following: I. CYTOGENETIC AND BIOLOGICAL STUDIES I.1. Plasmacytogenesis. a) Characterization of the murine plasmacytoma (MPC) precursor cell: b) Studies on the accelerating effect of A-MuLV on PC-genesis; c) Studies on the level of genetically determined PC- resistance in chimeric mice. I.2. Lymphomagenesis. Does consistutively expressed v-suppression: a) Does the normal fibroblast derived chromosome 15 contain a gene that counteracts tumorigenicity of T- leukemia cells with retrovirally rearranged c-myc or pvt-17: b) Do normal cells of different lineages carry suppressor genes on different chromosomes?: b) Do normal cells of different lineages carry suppressor genes on different chromosomes? c) Is suppressor loss involved in lymphoagenesis in conventional F1 and in transgenic mice?; d) Studies on a non-tumorigenic Burkitt lymphoma (BL) revertant. II.4. Studies on the decay of c-myc mRNA in normal and IgH/myc translocation-carrying cells; Ii.5 Continued studies on the rat immunocytoma associated IgH/myc translocation; II.6. Molecular studies of c-myc translocations to the functional heave chain producing chromosome in double heterozygous MPCs; II.7 Relationship between c-myc amplification and tumor progression in an experimentally modulatable mouse tumor system; II.8. Continued structural and functional studies on the B-myc gene; II.9 IgH-locus associated illegitimate translocations in pro-B-cells: a model for the IgH/myc translocation in Burkitt lymphoma?

这个项目是基于我们早期的研究结果， 鼠浆细胞瘤（MPG）发生过程中IgH/myc基因的表达 免疫细胞瘤与伯基特淋巴瘤的关系及chr 15的作用 小鼠T细胞白血病的三体性。这一领域主要是由 我们的细胞遗传学研究结果和衍生的工作假设，根据这一点， 格兰特.目前，许多实验室都在进行这项工作。我们选择 将我们继续的工作集中在几个选定的专题上， 实验室有特殊的经验，材料和/或开发了新的 工作假设我们目前的目标如下：一。细胞遗传学和 生物学研究浆细胞生成。a）表征 鼠浆细胞瘤（MPC）前体细胞：B）对促进MPC前体细胞增殖的研究 A-MuLV对PC-发生的影响; c）遗传水平的研究 在嵌合小鼠中测定PC抗性。 I.2.淋巴瘤并 组成性表达的V-抑制：a）正常成纤维细胞是否 衍生的15号染色体含有抵消T- 具有逆转录病毒重排的c-myc或pvt-17的白血病细胞：B）正常 不同谱系的细胞在不同的细胞上携带抑制基因， 染色体？：B）不同谱系的正常细胞是否携带抑制基因？ 不同染色体上的基因c）抑制基因丢失是否涉及 常规F1和转基因小鼠中的淋巴细胞生成？（一）研究a 非致瘤性伯基特淋巴瘤（BL）回复突变体。二.4.衰变研究 正常和携带IgH/myc易位的细胞中c-myc mRNA的表达; Ii.5 大鼠免疫细胞瘤相关IgH/myc易位的研究进展 二.6. c-myc基因转位至功能性Heavy的分子研究 双杂合MPC中的产链染色体; II.7关系 c-myc扩增和肿瘤进展之间的关系 可调节的小鼠肿瘤系统; II.8.结构和职能方面的持续 B-myc基因的研究; II.9 IgH基因座相关的非法 前B细胞中的IgH/myc易位： 伯基特淋巴瘤？